The 14 references in paper E. Panchenko P., Е. ПАНЧЕНКО П. (2015) “НОВЫЕ ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ У БОЛЬНЫХ НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ И ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК // NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE” / spz:neicon:aterotromboz:y:2015:i:2:p:51-57

1
Alonso et al. Сhronic kidney disease is associated with the incidence of atrial fibrillation. The Atherosclerosis risk in communities (ARIC) study. Circulation,2011. 123:
(check this in PDF content)
2
46–2953. 2. Go et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in AF. Circulation,2009. 119: 1363–1369.
(check this in PDF content)
3
Reinecke et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol,2009. 20: 705–711.
(check this in PDF content)
4
Ziad Hijazi et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation,2014. 129: 961–970.
(check this in PDF content)
5
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Eur Heart J.2012. 33(22): 2821–30.
(check this in PDF content)
6
Connolly SJ et al. for the AVERROES Steering Committee and investigetors. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011. 364: 806–817.
(check this in PDF content)
7
Patel et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation N Engl J Med. 2011. 365(10): 883–891.
(check this in PDF content)
8
K. Fox et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J,2011. doi:10.1093/eurheartj/ehr342
(check this in PDF content)
9
Nielsen PB et al. Renal function and non-vitamin K oral anticoagulation in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol, 2014. DOI 10.1007/s00392-014-0797-9.
(check this in PDF content)
10
Lega JC et al. Consistency of safety profileof new oral anticoagulants inpatients with renal failure. Thromb Haemost, 2014. 12(3): 337–43.
(check this in PDF content)
11
P.A. Reilly et al. The effect of dabigatran plasma concentration and patients characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. JACC,2014. 63(4): 321–8.
(check this in PDF content)
12
H. Heidbuchel et al. European Heart Rhythm Association bPractical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013. 15: 625–51.
(check this in PDF content)
13
Eikelboom JW et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulation therapy (RELY) trial. Circulation,2011. 123: 2363–72.
(check this in PDF content)
14
Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал, 2013. 4(102), приложение 3.
(check this in PDF content)